This inventor holds 1 USPTO granted patent. Top assignees: Hokkaido University, Kyoto University. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 442 
1 out of 870 
Years Active: 2026
Title: Ryuichiro Hirayama and Pharmaceutical Innovation in ADPKD Treatment.
Introduction
Ryuichiro Hirayama is an inventor associated with Kyoto, Japan. His listed patent concerns a proposed tamibarotene dosage regimen for treating autosomal dominant polycystic kidney disease (ADPKD).
Latest Patents
Hirayama is credited with 1 patent: “Pharmaceutical Composition for Treating Autosomal Dominant Polycystic Kidney Disease.” The patent describes an oral pharmaceutical composition containing tamibarotene for the treatment or prevention of ADPKD. It specifies a daily amount of 1.4–5.5 mg, with 4.0 mg identified as a particular dosage.
Career Highlights
The supplied information associates Hirayama with Hokkaido University and Kyoto University. These institutions provide context for his professional affiliations, though further details about his roles are not available here.
Collaborations
Hirayama’s listed coworkers include Fumihiko Hattanda and Tomoko Suzuki. Their names are associated with his collaborative work on the patent.
Conclusion
Ryuichiro Hirayama’s listed patent focuses on a tamibarotene-based oral dosage regimen for ADPKD, connecting his recorded innovation to pharmaceutical research and his university affiliations.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile